5:07 PM
 | 
Mar 11, 2013
 |  BC Extra  |  Clinical News

Pfizer reports Inspra data in STEMI patients

Pfizer Inc. (NYSE:PFE) said once-daily Inspra eplerenone initiated within 24 hours of the onset of ST-segment elevation myocardial infarction (STEMI) symptoms met the primary composite endpoint vs. placebo in the Phase III REMINDER trial. The study enrolled 1,012 acute STEMI patients without concomitant heart failure....

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >